Who should be next on Allergan's buyout list? We want your votes

Allergan ($AGN) has been on quite the buyout spree lately, and with $40.5 billion coming in from Teva ($TEVA) in exchange for its generics unit, it's about to settle some debt and get back to the dealmaking table. Who's next on CEO Brent Saunders' list, though, is anyone's guess, and we want to know what you think. Weigh in below on who you think Allergan should buy next and why--and feel free to write in an option if you think there's a good choice that's missing. We'll tally up the votes and get back to you with the results soon. Carly Helfand (email | Twitter)

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.